Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigimadlin and Ezabenlimab in Advanced Solid Tumors
NCT03964233Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of brigimadlin in solid tumor, Liposarcoma, undifferentiated pleomorphic sarcoma (UPS) and 7 more, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 21 days, Objective Response at 24 months and 1 more. Started Jun 2019; status: completed.
02
Drugs
brigimadlin
03
Conditions
solid tumorLiposarcomaundifferentiated pleomorphic sarcoma (UPS)myxofibrosarcoma (MFS)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT03964233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964233.